Targeted acid alpha-glucosidase therapeutics that localize to the lysosome are provided. The targeted therapeutics include amino acid residues 70-952 of acid alphaglucosidase (GAA), and a peptide tag comprising a portion of IGF2, permitting proper subcellular localization of the targeted therapeutic upon internalization of the therapeutic. The targeted therapeutics are useful for remedying insufficient GAA activity in the lysosome, i.e., Pompe disease. Nucleic acids, cells, and methods relating to the practice of the invention are also provided.